Article
From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.
Molecular diagnosis & therapy - 1 Jan 2026
Voutsadakis Ioannis A
Abstract excerpt
Inhibitors of kinase PI3K have been in clinical development for several years but only two drugs, the alpha catalytic sub-unit specific inhibitor alpelisib and more recently inavolisib, also an inhibitor of the alpha catalytic sub-unit, have been approved for a cancer indication, in metastatic breast cancer. In colorectal cancer, despite a high prevalence of PIK3CA gene mutations, PI3K inhibitors have met with...
Topics
Join the communities discussing this publication.